BICYCLE THERAPEUTICS PLC (BCYC)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 25M 50M 75M Q4 '18: 7.1M Q1 '19: 10.7M Q2 '19: 10.6M Q3 '19: 9.6M Q4 '19: 13.8M Q1 '20: 8.5M Q2 '20: 8.6M Q3 '20: 11.8M Q4 '20: 10.4M Q1 '21: 11.1M Q2 '21: 11.3M Q3 '21: 11.8M Q4 '21: 11.7M Q1 '22: 13.7M Q2 '22: 16.3M Q3 '22: 15M Q4 '22: 14.5M Q1 '23: 15.5M Q2 '23: 22.5M Q3 '23: 24.8M Q4 '23: 27M Q1 '24: 41.6M Q2 '24: 39.6M Q3 '24: 36.9M Q4 '24: 35.3M Q1 '25: 25.7M Q2 '25: 19.3M Q3 '25: 28.3M Q4 '25: 72.6M Q1 '26: 63.5M Q2 '26: 61.2M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-300M -200M -100M 0 100M 200M 300M Q4 '18: -21.7M Q1 '19: -22.2M Q2 '19: -25.2M Q3 '19: -29.1M Q4 '19: -26.3M Q1 '20: -34.6M Q2 '20: -39.2M Q3 '20: -39.7M Q4 '20: -52M Q1 '21: -56.3M Q2 '21: -61M Q3 '21: -64.7M Q4 '21: -65.6M Q1 '22: -77M Q2 '22: -87M Q3 '22: -102.5M Q4 '22: -116.7M Q1 '23: -131.1M Q2 '23: -146.9M Q3 '23: -167.9M Q4 '23: -189.9M Q1 '24: -179.9M Q2 '24: -183.4M Q3 '24: -196.4M Q4 '24: -209.9M Q1 '25: -248.4M Q2 '25: -288.3M Q3 '25: -290M Q4 '25: -247.1M Q1 '26: -242.3M Q2 '26: -210.3M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Net Income TTM

-270M -180M -90M 0 90M 180M 270M Q4 '18: -21.8M Q1 '19: -25.8M Q2 '19: -31.1M Q3 '19: -32.8M Q4 '19: -30.6M Q1 '20: -35.4M Q2 '20: -37.3M Q3 '20: -38M Q4 '20: -51M Q1 '21: -55.9M Q2 '21: -61.7M Q3 '21: -66.2M Q4 '21: -66.8M Q1 '22: -78.2M Q2 '22: -87.1M Q3 '22: -100.8M Q4 '22: -112.7M Q1 '23: -124.2M Q2 '23: -140M Q3 '23: -161.5M Q4 '23: -180.7M Q1 '24: -168.2M Q2 '24: -165.4M Q3 '24: -166.3M Q4 '24: -169M Q1 '25: -203.2M Q2 '25: -242.4M Q3 '25: -250.7M Q4 '25: -219M Q1 '26: -219M Q2 '26: -190.4M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-270M -180M -90M 0 90M 180M 270M Q2 '19: -26.3M Q3 '19: -32.5M Q4 '19: -28.6M Q1 '20: -2.2M Q2 '20: -7M Q3 '20: -6.1M Q4 '20: -17.8M Q1 '21: -52.7M Q2 '21: -52.7M Q3 '21: -21M Q4 '21: -14.8M Q1 '22: -27.5M Q2 '22: -38.6M Q3 '22: -66.2M Q4 '22: -86.1M Q1 '23: -106.1M Q2 '23: -48.5M Q3 '23: -43.6M Q4 '23: -60.6M Q1 '24: -85.1M Q2 '24: -163.8M Q3 '24: -202.6M Q4 '24: -164.7M Q1 '25: -180.2M Q2 '25: -208.4M Q3 '25: -239.7M Q4 '25: -249.7M Q1 '26: -229.2M Q2 '26: -206.1M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Free Cash Flow TTM

-270M -180M -90M 0 90M 180M 270M Q2 '19: -27.7M Q3 '19: -34.1M Q4 '19: -30.2M Q1 '20: -3.7M Q2 '20: -8.3M Q3 '20: -7.2M Q4 '20: -19M Q1 '21: -54.2M Q2 '21: -54.1M Q3 '21: -22.4M Q4 '21: -16.8M Q1 '22: -33.6M Q2 '22: -54.4M Q3 '22: -84.8M Q4 '22: -105.1M Q1 '23: -122.5M Q2 '23: -55.3M Q3 '23: -48M Q4 '23: -63.6M Q1 '24: -85.9M Q2 '24: -164.8M Q3 '24: -203.5M Q4 '24: -166M Q1 '25: -182.1M Q2 '25: -210.3M Q3 '25: -241.9M Q4 '25: -252M Q1 '26: -231.7M Q2 '26: -208.3M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 25M 50M 75M Q2 '20: 18.1M Q3 '20: 19.4M Q1 '21: 22.1M Q2 '21: 24.1M Q3 '21: 25M Q1 '22: 29.6M Q2 '22: 29.6M Q3 '22: 29.7M Q1 '23: 30M Q2 '23: 30.2M Q3 '23: 39.6M Q1 '24: 42.6M Q2 '24: 52M Q3 '24: 69M Q1 '25: 69.2M Q2 '25: 69.3M Q3 '25: 69.3M Q1 '26: 69.7M Q2 '26: 69.8M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-60.00 -40.00 -20.00 0.00 20.00 40.00 60.00 Q4 '18: -49.15 Q1 '19: -50.57 Q2 '19: -40.12 Q3 '19: -22.92 Q4 '19: -9.98 Q1 '20: -2.81 Q2 '20: -2.08 Q3 '20: -2.07 Q4 '20: -2.67 Q1 '21: -2.77 Q2 '21: -2.84 Q3 '21: -2.91 Q4 '21: -2.67 Q1 '22: -2.87 Q2 '22: -3.03 Q3 '22: -3.40 Q4 '22: -3.80 Q1 '23: -4.17 Q2 '23: -4.68 Q3 '23: -4.98 Q4 '23: -5.10 Q1 '24: -4.42 Q2 '24: -3.78 Q3 '24: -3.26 Q4 '24: -2.88 Q1 '25: -3.14 Q2 '25: -3.51 Q3 '25: -3.62 Q4 '25: -3.16 Q1 '26: -3.15 Q2 '26: -2.73 Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.